Spectromics Company
![](/files/companies/Spectromics%20(ManCOM).jpg)
Spectromics develops a diagnostic system that helps to guide antibiotic treatment. It provides a fast, simple, accurate, and cost-effective test for bacterial infections that identifies anti-microbial susceptibility/resistance during a patient appointment. Then includes guidance on the most effective treatment for a particular pathogen and which drug to prescribe. Spectromics focuses its internal activities on technology development whilst engaging with partners who bring complementary expertise in instrument development/production and cartridge manufacture. The novel and proprietary technology are based on spectrometric monitoring of phenotypic change that occurs in reactions between the sample and a candidate antibiotic panel.
Headquarters:
Manchester, United Kingdom
Last Funding Type:
Series A
Investors Number:
2
Last Funding Date:
06-29-2015
Employee Number:
1-10
Founded Date:
2014
Estimated Revenue:
< £780 000
Industry:
P4 medicine
Funding Status:
Early Stage Venture